全部商品分类首页
PF-04991532
用小程序，查商品更便捷
产品介绍
产品介绍
产品信息
抗原名称
GK (rat):100 nM（EC50）, GK (human):（EC50）80 nM
简单描述
PF-04991532 is an effective, hepatoselective glucokinase activator. It has EC50s of 80 and 100 nM in human and rat, respectively.
商品描述
PF-04991532 is an effective, hepatoselective glucokinase activator. It has EC50s of 80 and 100 nM in human and rat, respectively.
分子量
396.36
纯度
0
性状
0
颜色
0
In vitro(体外研究)
PF-04991532 is a Phase 2 clinical candidate. PF-04991532 reduces the production of glucose from 1-[14C]-lactate in a dose-dependent manner (EC50?=0.626 μM). PF-04991532 enhances the expression of G6Pase compare to cells treated only with 100 nM glucagon, in isolated rat hepatocytes. The greatest increase in G6Pase mRNA expression is in the presence of 25 mM glucose, 100 nM glucagon, and PF-04991532. Mechanistic experiments conducted in freshly isolated primary rat hepatocytes treated for 1 hour with PF-04991532 display increased 2-[14C]-deoxyglucose uptake (EC50?=1.261 μM) and increased glucose oxidation (EC50=5.769 μM) [1].
In vivo(体内研究)
PF-04991532 (a single dose) enhances the glucose infusion rate in order to maintain hyperglycemia. PF-04991532 (in rats) treatment, there is increased expression of lipogenic gene expression such as acetyl-CoA carboxylase (ACC), ATP citrate lyase (ACLY), and fatty acid synthase (FAS). Despite the elevations in plasma triglycerides, hepatic triglycerides in rats dosed with 19 days of PF-04991532 are identical to vehicle-treated GK rats. Identical hepatic lipid concentrations are observed between vehicle and rats dosed with PF-04991532 (Vehicle: 9.89±0.31; PF-04991532 100 mg/kg: 9.91±0.31), in an additional cohort treated for 28 days [1].
背景
别名
0
分子式
C18H19F3N4O3
CAS号
1215197-37-7
密度
1.48 g/cm3 (Predicted)
制备和贮存
溶解方法
0
存储溶液
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
声明 ：本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。